Hosni was appointed CEO in 2021. In the first nine months of 2025, Jamjoom Pharma’s three manufacturing facilities produced 128 million units. During the same period, the company launched six new brands, bringing its total portfolio to 147 brands. It also reported a 13% year-on-year increase in revenue, reaching $319 million. In October 2025, Jamjoom Pharma and Lifera announced plans for a potential joint venture to develop, manufacture, and commercialize vaccines, biologics, and biosimilars in Saudi Arabia. In October 2025, Jamjoom Pharma unveiled a new brand identity to accelerate regional and global growth. Hosni previously held leadership roles at Pfizer and GSK.